Institution
ACADIA Pharmaceuticals Inc.
Company•San Diego, California, United States•
About: ACADIA Pharmaceuticals Inc. is a company organization based out in San Diego, California, United States. It is known for research contribution in the topics: Pimavanserin & Receptor. The organization has 260 authors who have published 276 publications receiving 8418 citations.
Papers published on a yearly basis
Papers
More filters
Patent•
03 May 2006TL;DR: In this article, crystalline forms A, B, C, D, and E of N-desmethylclozapine, methods of preparing the same and pharmaceutical compositions comprising the same, and methods of therapeutic treatment involving Ndesmethyl clozapines polymorphic forms are presented.
Abstract: Disclosed herein are crystalline Forms A, B, C, D, and E of N-desmethylclozapine, methods of preparing the same, pharmaceutical compositions comprising the same, and methods of therapeutic treatment involving N-desmethylclozapine polymorphic forms.
7 citations
TL;DR: It is concluded that this evolutionary important patch mediates interactions important for maintaining the inactive state in the AT1 receptor are consistent with computational predictions of a generic role for this patch in 7TM receptor activation.
7 citations
Patent•
23 Mar 2017TL;DR: In this article, the authors proposed a method for treating a disease or disorder in a patient who is currently taking a cytochrome P450 inhibitor comprising administering to the patient a dose of pimavanserin or a pharmaceutical acceptable salt thereof, wherein the dose is at least 20% lower than the dose that would otherwise have been recommended.
Abstract: A method for treating a disease or disorder in a patient who is currently taking a cytochrome P450 inhibitor comprising administering to the patient a dose of pimavanserin or a pharmaceutical acceptable salt thereof, wherein the dose is at least 20% lower than a dose of pimavanserin or a pharmaceutical acceptable salt thereof that would otherwise have been recommended to the patient if the patient were not currently taking the cytochrome P450 inhibitor.
6 citations
TL;DR: In this article, the authors presented the durability of response with pimavanserin in patients with Parkinson's disease psychosis (PDP) for an additional 4 weeks of treatment.
6 citations
TL;DR: Adjunctive pimavanserin was not associated with an increase in suicidal ideation in patients with MDD and an inadequate response to a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptakes inhibitor (SNRI).
6 citations
Authors
Showing all 261 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Michael Bachmann | 63 | 360 | 14388 |
| Daniel P. van Kammen | 47 | 168 | 6957 |
| Kristina Luthman | 39 | 158 | 7344 |
| Fredrik Almqvist | 37 | 170 | 4219 |
| Mark R. Brann | 35 | 77 | 5579 |
| Roger Olsson | 30 | 138 | 2752 |
| Uli Hacksell | 29 | 99 | 2954 |
| Torbjörn Frejd | 29 | 165 | 2889 |
| Petrine Wellendorph | 27 | 83 | 2573 |
| Ethan S. Burstein | 27 | 70 | 2255 |
| David M. Weiner | 26 | 45 | 3230 |
| Kimberly E. Vanover | 25 | 70 | 1955 |
| Uli Hacksell | 25 | 129 | 2879 |
| Magnus Gustafsson | 25 | 94 | 1546 |
| Mark R. Brann | 24 | 39 | 2576 |